Accessibility Menu
Rising BioSciences logo

Rising BioSciences(OTC) RBII

Market Cap$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Rising BioSciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-13
Rising BioSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 0.002026-07-02
1 month+0%USD 0.002026-05-27
3 month+0%USD 0.002026-04-07
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-07-10
3 year+0%USD 0.002023-07-05
5 year-99.75%USD 0.002021-07-14
Since inception-99.99%USD 0.012017-04-28

Rising BioSciences Financials at a Glance

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-27.98 (Low)

Price

$0.00

Volume

180,183

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

RBII News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rising BioSciences

Rising Biosciences, Inc. is a healthcare company focused on developing and manufacturing topical and oral pharmaceutical products, including medical marijuana products. Based in Sheridan, Wyoming, the company aims to innovate within the medical and pharmaceutical sectors.

Products and Services
  • Topical pharmaceutical products for various medical conditions
  • Oral pharmaceutical products, including medical marijuana
  • Research and development of new therapeutic solutions
Growth Outlook
  • Significant market potential in the medical marijuana sector
  • Increasing demand for innovative pharmaceutical products
  • Focus on expanding product lines to capture new customer segments
Financial Highlights
  • Recent revenue of $0.00001 per share, indicating growth potential
  • Trailing twelve months (TTM) gross profit margin of 57.3%
  • Operating profit margin of 36.3%, showcasing operational efficiency
Rising Biosciences, Inc. operates in a rapidly evolving industry, with a strong emphasis on innovation and product development. The company's focus on medical marijuana products positions it well within a growing market, as consumer interest in alternative therapies continues to rise. The financial metrics indicate a solid foundation, with a notable gross profit margin and operating profit margin, suggesting effective management of resources and potential for profitability. As the company seeks to expand its product offerings, it may attract further interest from investors looking for opportunities in the healthcare sector.
AI Generated • Jul 7, 2026

Industry

Pharmaceuticals

Headquarters

Sheridan, WY 82801, US

RBII Financials

Key Financial Metrics (TTM)

Gross Margin

57.32%

Operating Margin

36.33%

Net Income Margin

6.36%

Return on Equity

-4.43%

Return on Capital

N/A

Return on Assets

7.77%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

499.14M

Volume

180.18K

Avg. Volume

14.61K

Financials (TTM)

Gross Profit

$448.38K

Operating Income

$284.17K

EBITDA

$152.69K

Operating Cash Flow

-$70.34K

Capital Expenditure

$3.00

Free Cash Flow

-$70.34K

Cash & ST Invst.

$48.00K

Total Debt

$1.06M

Rising BioSciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AXMPAXM Pharma, Inc.
$0.00+0.00%
ISOLFIsodiol International Inc.
$0.00+0.00%
OWCPOWC Pharmaceutical Research Corp.
$0.00+0.00%
NNBPNanobac Pharmaceuticals, Incorporated
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
EAElectronic Arts
$209.70-0.00%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.26-0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.07+0.03%
INTCIntel
$100.86+0.11%

Questions About RBII

What is the current price of Rising BioSciences?

Rising BioSciences is trading at $0.00 per share.

What is the 52-week range for Rising BioSciences?

Over the past 52 weeks, Rising BioSciences has traded between $0.00 and $0.00.

How much debt does Rising BioSciences have?

Rising BioSciences total debt is unavailable.

How much cash does Rising BioSciences have on hand?

Rising BioSciences does not have cash on hand data available.

What is Rising BioSciences’s dividend yield?

Rising BioSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.